Repositioning Candidate Details
| Candidate ID: | R0770 |
| Source ID: | DB05319 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Oportuzumab monatox |
| Synonyms: | Oportuzumab monatox |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin A. |
| CAS Number: | 945228-48-8 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in bladder cancer and head and neck cancer. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | VB4-845 binds to EpCAM (a protein on the surface of epithelial cells and some types of cancer cells). Also called anti-EpCAM-Pseudomonas-exotoxin fusion protein and Proxinium. It targets and kills Ep-CAM-positive tumors by apoptosis. |
| Targets: | Epithelial cell adhesion molecule |
| Inclusion Criteria: | Therapeutic strategy associated |
